Rimantadine

Rimantadine is a synthetic adamantane antiviral, the alpha-methyl analog of amantadine, marketed in the United States under the brand name Flumadine. Like amantadine it belongs to the M2 ion-channel inhibitor class and is active exclusively against influenza A, working by plugging the viral M2 proton channel and thereby blocking uncoating. It was approved by the US Food and Drug Administration in 1993 for the prophylaxis and treatment of influenza A in adults and for prophylaxis in children, and it saw substantial earlier clinical use in the Soviet Union.

Clinically, rimantadine occupied a niche defined largely by comparison with its parent. Randomized trials established prophylactic efficacy in the range of 70 to 90 percent against laboratory-confirmed influenza A and modest treatment benefit when started within the first day or two of illness, broadly comparable to amantadine ^[2]. Its principal advantage was tolerability: extensive hepatic metabolism, lower central nervous system penetration, and a long half-life permitting simple dosing made it the preferred adamantane for elderly patients and those prone to amantadine's neurologic side effects ^[3][4]. Its principal limitations were the same as amantadine's, namely no activity against influenza B and the rapid emergence of resistant virus during treatment.

Rimantadine is today effectively obsolete for seasonal influenza. Following the near-universal spread of the S31N M2 mutation, the US Centers for Disease Control and Prevention recommended against the use of adamantanes for influenza beginning in the 2005 to 2006 season, and the neuraminidase inhibitors and later baloxavir supplanted the class ^[5]. The drug retains value chiefly as a pharmacological reference point, illustrating how a small structural change to a scaffold can improve tolerability without changing the antiviral target, and as a probe compound in structural studies of the M2 channel and its resistance mutations.

Rimantadine is a prescription antiviral with a long human track record; when it still worked, it was generally better tolerated than amantadine, with fewer central nervous system effects such as insomnia, jitteriness, or trouble concentrating, though gastrointestinal upset can occur. Its bigger problem today is futility rather than toxicity: widespread M2 resistance means it will not reliably treat modern influenza A, so neuraminidase inhibitors or newer agents are preferred. It is cleared partly by the kidneys and liver, so dosing is adjusted in older adults and in kidney or liver impairment. Do not treat this as medical advice or self-prescribe an antiviral.

Rimantadine has notably few drug interactions, and those that have been measured are small. Coadministration with acetaminophen reduced rimantadine peak concentration and AUC by roughly 11%, and aspirin by roughly 10%; neither change is large enough to have shown a clinical effect. Cimetidine, a broad enzyme inhibitor that raises the levels of many drugs, produced no statistically significant change in rimantadine exposure in a single-dose study.

The interaction that does carry practical weight is not pharmacokinetic at all. Live attenuated intranasal influenza vaccine and rimantadine interfere with each other, because an active antiviral suppresses replication of the vaccine strain and blunts the immune response the vaccine is meant to provoke. Labeling separates the two, by 48 hours after rimantadine stops and by two weeks after vaccination.

Rimantadine is extensively hydroxylated and conjugated before renal excretion, and no clinically significant cytochrome P450 interactions have been established for it.

Checking a whole stack? Run it through interactions + stacks.

Rimantadine emerged from adamantane chemistry in the 1960s as a close structural relative of amantadine, the first M2 inhibitor. It was studied and deployed extensively in the Soviet Union for influenza prophylaxis and treatment well before it reached Western markets, with controlled outbreak studies in the 1970s reporting therapeutic and prophylactic benefit in family and community settings. In the United States a landmark placebo-controlled trial published in the New England Journal of Medicine in 1982 compared rimantadine and amantadine directly and concluded that rimantadine, with efficacy comparable to amantadine but fewer central nervous system side effects, appeared to be the drug of choice for influenza A prophylaxis ^[2]; the drug was ultimately approved by the FDA as Flumadine in 1993.

Rimantadine is generally regarded as the better-tolerated of the two adamantanes: about as effective as amantadine against influenza A but far less likely to cause the confusion, insomnia, and other neurologic effects that limit amantadine, especially in the elderly and in patients with renal impairment ^[2][4]. That favorable safety profile, however, is now largely academic. Because it shares amantadine's M2 target, rimantadine also shares its fatal weakness, cross-resistance conferred by the S31N mutation that swept through circulating influenza A strains, and it has no activity against influenza B. It is consequently viewed as clinically obsolete for seasonal influenza and is no longer recommended, remembered mainly as a well-designed drug defeated by viral evolution ^[5].